Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 10521505 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Lim CP, Cao X (1999) Serine phosphorylation and negative regulation of Stat3 by JNK. J Biol Chem 274, 31055-61 10521505
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T183-p - JNK1 (human) ▲
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  monkey
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
STAT3 (human) no change compared to control
EGF no change compared to control
EGF MKK7 (human), STAT3 (human) no change compared to control
EGF JNK1 (human), STAT3 (human) no change compared to control
EGF JNK1 (human), MKK7 (human), STAT3 (human) increase
EGF JNK1 (human), MKK7 (human), STAT3 (human) no change compared to control JNK1 -/-
JNK1 (human), MKK7 (human), STAT3 (human) no change compared to control MKK7 -/-
EGF augment treatment-induced decrease

Y185-p - JNK1 (human) ▲
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  monkey
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
STAT3 (human) no change compared to control
EGF no change compared to control
EGF MKK7 (human), STAT3 (human) no change compared to control
EGF JNK1 (human), STAT3 (human) no change compared to control
EGF JNK1 (human), MKK7 (human), STAT3 (human) increase
EGF JNK1 (human), MKK7 (human), STAT3 (human) no change compared to control JNK1 -/-
JNK1 (human), MKK7 (human), STAT3 (human) no change compared to control MKK7 -/-
EGF augment treatment-induced decrease

Y705-p - STAT3 (human) ▲
Orthologous residues
STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 iso3 (human): Y705‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  monkey
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
STAT3 (human) no change compared to control
EGF STAT3 (human) increase
EGF JNK1 (human), STAT3 (human) STAT3 (human) no effect upon treatment-induced increase
EGF JNK1 (human), STAT3 (human) STAT3 (human) no effect upon treatment-induced increase JNK1 -/-
EGF JNK1 (human), MKK7 (human), STAT3 (human) STAT3 (human) inhibit treatment-induced increase
EGF JNK1 (human), MKK7 (human), STAT3 (human) STAT3 (human) no effect upon treatment-induced increase MKK7 -/- slight decrease
EGF increase
UV EGF inhibit treatment-induced increase

S727-p - STAT3 (human) ▲
Orthologous residues
STAT3 (human): S727‑p, STAT3 iso2 (human): S726‑p, STAT3 iso3 (human): ‑, STAT3 (mouse): S727‑p, STAT3 iso2 (mouse): ‑, STAT3 iso3 (mouse): S726‑p, STAT3 (rat): S727‑p, STAT3 (cow): S727‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  monkey
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE JNK1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE JNK1 (human) activation of upstream enzyme, phospho-antibody, transfection of wild-type enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase
SB203580 UV no effect upon treatment-induced increase
PD98059 UV no effect upon treatment-induced increase
anisomycin increase
TNF increase
arsenite increase
NaCl no change compared to control NaCl, okadaic acid, and LPS showed a weaker increase
okadaic acid increase
LPS increase
EGF increase very strong induction
SB203580 EGF no effect upon treatment-induced increase
PD98059 EGF inhibit treatment-induced increase
PD98059 decrease
SB203580 decrease
Downstream Regulation
 Effect of modification (function):  inhibition
 Effect of modification (process):  transcription, altered


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.